Lexicon Pharmaceuticals Inc. (LXRX)
$2.26
$0.02
(0.89%)
As on 03-Sep-2026 16:00EDT
Market cap
$1,019 Mln
Revenue (TTM)
$41 Mln
P/E Ratio
--
P/B Ratio
5.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
16.6
-
Debt to Equity
0.3
-
Book Value
$--
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
444,955,934
10 Years Aggregate
CFO
$-767.40 Mln
EBITDA
$-799.88 Mln
Net Profit
$-804.57 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
| 96.5 | -2.2 | 19.6 | 101.8 | 10.2 | -14.3 | -16.8 |
|
BSE Sensex*
| -9.4 | -2.4 | 3.2 | -4.8 | 5.5 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
| 55.7 | -51.4 | -19.9 | -51.5 | 15.2 | -17.6 | -37.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
2.3 | 1,019.0 | 41.5 | -61.1 | -127.2 | -43.3 | -- | 5.9 |
| 86.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 271.1 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 74.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.8 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 371.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.6 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.4 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 355.2 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small... molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. Read more
-
CEO & Director
Mr. Lonnel Coats
-
CEO & Director
Mr. Lonnel Coats
-
Headquarters
The Woodlands, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Lexicon Pharmaceuticals (LXRX)
What is the current share price of Lexicon Pharmaceuticals Inc (LXRX) Today?
The share price of Lexicon Pharmaceuticals Inc (LXRX) is $2.26 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Lexicon Pharmaceuticals Inc (LXRX) has given a return of 10.17% in the last 3 years.
What is the current PB & PE ratio of Lexicon Pharmaceuticals Inc (LXRX)?
Since, TTM earnings of Lexicon Pharmaceuticals Inc (LXRX) is negative, P/E ratio is not available.
The P/B ratio of Lexicon Pharmaceuticals Inc (LXRX) is 5.94 times as on 28-Aug-2026, a 15 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-8.30 |
3.89 |
2024 |
-1.33 |
1.83 |
2023 |
-2.12 |
4.02 |
2022 |
-3.54 |
3.08 |
2021 |
-6.68 |
5.16 |
What is the 52 Week High and Low of Lexicon Pharmaceuticals Inc (LXRX)?
The 52-week high and low of Lexicon Pharmaceuticals Inc (LXRX) are Rs 2.68 and Rs 1.05 as of 04-Sep-2026.
What is the market cap of Lexicon Pharmaceuticals Inc (LXRX)?
Lexicon Pharmaceuticals Inc (LXRX) has a market capitalisation of $ 1,019 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Lexicon Pharmaceuticals Inc (LXRX)?
Before investing in Lexicon Pharmaceuticals Inc (LXRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.